Thurtle DR, et al. - Authors investigated 10,089 men to establish and validate an individualized prognostic model to study prostate cancer (PCa)-specific mortality (PCSM) vs other causes of mortality and to estimate the influence of treatment on survival. They also noted multiple cases who suffered lifelong side effects from a treatment they might not have needed. They reported a new risk model, named 'PREDICT Prostate,' which predicted survival outcomes with a high degree of accuracy for conservative management and radical treatment, with concordance indices up to 0.84.